Author:
Tohen Mauricio,Chengappa K. N. Roy,Suppes Trisha,Baker Robert W.,Zarate Carlos A.,Bowden Charles L.,Sachs Gary S.,Kupfer David J.,Ghaemi S. Nassir,Feldman Peter D.,Risser Richard C.,Evans Angela R.,Calabrese Joseph R.
Abstract
BackgroundFew controlled studies have examined the use of atypical antipsychotic drugs for prevention of relapse in patients with bipolar I disorder.AimsTo evaluate whether olanzapine plus either lithium or valproate reduces the rate of relapse, compared with lithium or valproate alone.MethodPatients achieving syndromic remission after 6 weeks'treatment with olanzapine plus either lithium (0.6–1.2 mmol/l) or valproate (50–125 μg/ml) received lithium or valproate plus either olanzapine 5–20 mg/day (combination therapy) or placebo (monotherapy), and were followed in a double-masked trial for 18 months.ResultsThe treatment difference in time to relapse into either mania or depression was not significant for syndromic relapse (median time to relapse: combination therapy 94 days, monotherapy40.5 days; P=0.742), but was significant for symptomatic relapse (combination therapy 163 days, monotherapy42 days; P=0.023).ConclusionsPatients taking olanzapine added to lithium or valproate experienced sustained symptomatic remission, but not syndromic remission, for longer than those receiving lithium or valproate monotherapy.
Publisher
Royal College of Psychiatrists
Subject
Psychiatry and Mental health
Cited by
264 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献